Clinical Trial Update: A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating sintilimab in combination with apatinib and capecitabine for advanced hepatocellular carcinoma is ongoing with an unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Capecitabine (capecitabine)
• Sintilimab (sintilimab)

Snippet

Sponsor: Xin-Hua Xu | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN